Ausgabe 5/2021
Inhalt (27 Artikel)
Stress relief for cancer immunotherapy: implications for the ER stress response in tumor immunity
- Review
Alex M. Andrews, Megan D. Tennant, Jessica E. Thaxton
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
- Review
Elena María Brozos-Vázquez, Roberto Díaz-Peña, Jorge García-González, Luis León-Mateos, Patricia Mondelo-Macía, María Peña-Chilet, Rafael López-López
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer
- Original Article
Tao Dao, Martin G. Klatt, Tatyana Korontsvit, Sung Soo Mun, Sean Guzman, Marissa Mattar, Oliver Zivanovic, Chrisann K. Kyi, Nicholas D. Socci, Roisin E. O’Cearbhaill, David A. Scheinberg
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect
- Original Article
Jiyun Lee, Binnari Kim, Hyun Ae Jung, Yoon La Choi, Jong-Mu Sun
B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis
- Original Article
Huimin Lu, Yanchao Ma, Mingyuan Wang, Jin Shen, Hongya Wu, Juntao Li, Nan Gao, Yanzheng Gu, Xueguang Zhang, Guangbo Zhang, Tongguo Shi, Weichang Chen
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas
- Original Article
Farah Succaria, Pia Kvistborg, Julie E. Stein, Elizabeth L. Engle, Tracee L. McMiller, Lisa M. Rooper, Elizabeth Thompson, Alan E. Berger, Michiel van den Brekel, Charlotte L. Zuur, John Haanen, Suzanne L. Topalian, Janis M. Taube
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy
- Open Access
- Original Article
Ayaka Hara, Ryo Koyama-Nasu, Mariko Takami, Takahide Toyoda, Takahiro Aoki, Fumie Ihara, Masayoshi Kobayashi, Seiichiro Hirono, Tomoo Matsutani, Toshinori Nakayama, Yasuo Iwadate, Shinichiro Motohashi
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
- Original Article
Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, Alfredo Addeo, Miklos Pless, Sacha I. Rothschild, Wolf-Dieter Janthur, Henning Burmeister, Alex Friedlaender, Martina Schneider, Yannis Metaxas, Markus Joerger, Luciano Wannesson, Michael Schwitter, Nathalie Baudoux, Susanne Weindler, Christine Biaggi-Rudolf, Martin Früh
Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients
- Open Access
- Original Article
Wolfgang M. Thaiss, Sergios Gatidis, Tina Sartorius, Jürgen Machann, Andreas Peter, Thomas K. Eigentler, Konstantin Nikolaou, Bernd J. Pichler, Manfred Kneilling
Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy
- Open Access
- Original Article
Mikołaj Piotr Zaborowski, Patrycja Stefens-Stawna, Krystyna Osztynowicz, Tomasz Piorunek, Halina Batura-Gabryel, Agnieszka Dyzmann-Sroka, Wojciech Kozubski, Ewa Nowak-Markwitz, Sławomir Michalak
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters
- Original Article
Lata Singh, Mithalesh Kumar Singh, Maria Cristina Kenney, Martine J. Jager, Moshahid Alam Rizvi, Rachna Meel, Neiwete Lomi, Sameer Bakhshi, Seema Sen, Seema Kashyap
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells
- Open Access
- Original Article
J. M. R. Van der Meer, R. J. A. Maas, K. Guldevall, K. Klarenaar, P. K. J. D. de Jonge, J. S. Hoogstad-van Evert, A. B. van der Waart, J. Cany, J. T. Safrit, J. H. Lee, E. Wagena, P. Friedl, B. Önfelt, L. F. Massuger, N. P. M. Schaap, J. H. Jansen, W. Hobo, H. Dolstra
In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes
- Original Article
Maryam Moradi-Chaleshtori, Mojgan Bandehpour, Sara Soudi, Samira Mohammadi-Yeganeh, Seyed Mahmoud Hashemi
Correction to: In vitro and in vivo evaluation of anti‑tumoral effect of M1 phenotype induction in macrophages by miR‑130 and miR‑33 containing exosomes
- Correction
Maryam Moradi-Chaleshtori, Mojgan Bandehpour, Sara Soudi, Samira Mohammadi-Yeganeh, Seyed Mahmoud Hashemi
The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors
- Open Access
- Original Article
Anne Scheuerpflug, Fatima Ahmetlić, Vera Bauer, Tanja Riedel, Martin Röcken, Ralph Mocikat
Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression
- Original Article
Chun-Chia Cheng, Hsin-Chi Lin, Ya-Wen Chiang, Jungshan Chang, Zong-Lin Sie, Bi-Ling Yang, Ken-Hong Lim, Cheng-Liang Peng, Ai-Sheng Ho, Yi-Fang Chang
Prognostic significance of S100A8-positive immune cells in relation to other immune cell infiltration in pre-invasive and invasive breast cancers
- Open Access
- Original Article
Ji Won Woo, Yul Ri Chung, Milim Kim, Hye Yeon Choi, Soomin Ahn, So Yeon Park
IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas
- Open Access
- Original Article
Arianna Di Napoli, Daniele Greco, Giorgia Scafetta, Francesca Ascenzi, Alessandro Gulino, Luigi Aurisicchio, Fabio Santanelli Di Pompeo, Adriana Bonifacino, Enrico Giarnieri, John Morgan, Rita Mancini, Marshall E. Kadin
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution
- Open Access
- Original Article
R. Kleef, R. Nagy, A. Baierl, V. Bacher, H. Bojar, D. L. McKee, R. Moss, N. H. Thoennissen, M. Szász, T. Bakacs
Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma
- Original Article
Yusuke Mochizuki, Hiroshi Tazawa, Koji Demiya, Miho Kure, Hiroya Kondo, Tadashi Komatsubara, Kazuhisa Sugiu, Joe Hasei, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara
Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models
- Open Access
- Original Article
Chi-Ping Huang, Chun-Chie Wu, Chih-Rong Shyr
The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer
- Open Access
- Original Article
Ming-Fang Wu, Chih-An Lin, Tzu-Hang Yuan, Hsiang-Yuan Yeh, Sheng-Fang Su, Chin-Lin Guo, Gee-Chen Chang, Ker-Chau Li, Chao-Chi Ho, Huei-Wen Chen
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells
- Open Access
- Original Article
Farsaneh Sadeghlar, Annabelle Vogt, Raphael U. Mohr, Robert Mahn, Katrin van Beekum, Miroslaw Kornek, Tobias J. Weismüller, Vittorio Branchi, Hanno Matthaei, Marieta Toma, I. G. H. Schmidt-Wolf, Jörg C. Kalff, Christian P. Strassburg, Maria A. González-Carmona
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement
- Original Article
Phillip M. Kemp Bohan, Robert C. Chick, Annelies T. Hickerson, Lynn M. Messersmith, Grant M. Williams, Jessica L. Cindass, Jamie Lombardo, Ryan Collins, Robert O. Brady, Diane F. Hale, George E. Peoples, Timothy J. Vreeland, Guy T. Clifton
Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment
- Original Article
Louis T. Curtis, Susanne Sebens, Hermann B. Frieboes
Correction to: Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment
- Correction
Louis T. Curtis, Susanne Sebens, Hermann B. Frieboes
Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
- Open Access
- Research Report
M. Schuiveling, E. H. J. Tonk, R. J. Verheijden, K. P. M. Suijkerbuijk
